Panelists discuss how LEAP-012 trial results show promising progression-free survival, while anticipating further data on overall survival outcomes.
Dose Reductions of Liposomal Irinotecan, Oxaliplatin Don’t Affect OS in Metastatic PDAC
Dose reductions of liposomal irinotecan and oxaliplatin did not compromise overall survival in patients with metastatic PDAC on NALIRIFOX.
Read More
LaPelusa’s Journey in the Dynamic Field of GI Oncology
In this episode of Emerging Experts, Michael LaPelusa, MD, shares his insights, experiences, and passion for cancer research, particularly in the realm of gastrointestinal cancers.
Listen
ASCEND Trial of Certepetide Plus Chemo Fails to Improve PFS in Metastatic PDAC
Certepetide plus chemotherapy showed signs of efficacy but failed to improve progression-free survival in metastatic PDAC in the ASCEND trial.
Unpacking the Latest Research in Gastrointestinal Cancers
In season 4, episode 1 of Targeted Talks, Benjamin L. Schlechter, MD, discuses new studies in the gastrointestinal cancers space.
Pelareorep + FOLFIRINOX ± Atezolizumab Safe in Metastatic PDAC: GOBLET Study
The combination of pelareorep and modified FOLFIRINOX with or without atezolizumab had an acceptable safety in newly diagnosed metastatic pancreatic ductal adenocarcinoma.
Zoldonrasib Shows Promise in KRAS G12D–Mutated PDAC
Zoldonrasib showed preliminary antitumor activity and manageable adverse events in KRAS G12D–mutated PDAC, per phase 1 trial data.